ASTRAZENECA PHARMA INDIA LTD.
NSE : ASTRAZENBSE : 506820ISIN
CODE : INE203A01020Industry : Pharmaceuticals & DrugsHouse
: Astrazeneca Pharma India - MNC
BSE5341.25-214.85 (-3.87 % )
PREV CLOSE (Rs.) 5556.10
OPEN PRICE (Rs.) 5450.00
BID PRICE (QTY) 0.00 (0 )
OFFER PRICE (QTY) 0.00 (0 )
VOLUME 3466
TODAY'S LOW / HIGH (Rs.)
52 WK LOW / HIGH (Rs.)
NSE5335.30 -219.45 (-3.95 % )
PREV CLOSE(Rs.) 5554.75
OPEN PRICE (Rs.) 5475.10
BID PRICE (QTY) 5335.30 (7 )
OFFER PRICE (QTY) 0.00 (0 )
VOLUME 65392
TODAY'S LOW / HIGH(Rs.)
52 WK LOW / HIGH (Rs.)
Company News
| Date | Heading | Details |
|---|---|---|
| 27-Mar-2024 | AstraZeneca Pharma gets nod to import for sale, distribution of Trastuzumab deruxtecan lyophilized powder | <p style="text-align: justify;">AstraZeneca Pharma India has received permission to import for sale and distribution of Trastuzumab deruxtecan lyophilized powder for concentrate for solution for infusion 100mg (Enhertu) from the Central Drugs Standard Control Organisation, Directorate General of Health Services, Government of India. </p><p style="text-align: justify;">Trastuzumab deruxtecan is indicated for the treatment of adult patients with unresectable or metastatic HER2-Low (IHC 1+ or IHC 2+/ISH-) breast cancer who have received a prior chemotherapy in the metastatic setting or developed disease recurrence during or within 6 months of completing adjuvant chemotherapy.</p><p style="text-align: justify;">It is also indicated for the treatment of adult patients with locally advanced or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma who have received a prior trastuzumab based regimen.</p><p style="text-align: justify;">The receipt of this permission paves way for the launch of Trastuzumab deruxtecan lyophilized powder for concentrate for solution for infusion 100mg (Enhertu) in India for the specified additional indications, subject to the receipt of related statutory approvals, if any.</p><p style="text-align: justify;">AstraZeneca Pharma India is a global biopharmaceutical company. The company is engaged in the discovery, development and commercialization of medicines for core areas of healthcare, including cardiovascular/metabolic disease, cancer and respiratory, inflammatory and autoimmune disease. The company operates through two segments Healthcare and Clinical Trial.</p> |
| 27-Mar-2024 | AstraZeneca Pharma surges on getting nod to import for sale, distribution of Trastuzumab deruxtecan lyophilized powder | <p style="text-align: justify;">Astrazeneca Pharma India is currently trading at Rs. 5258.00, up by 198.45 points or 3.92% from its previous closing of Rs. 5059.55 on the BSE.</p><p style="text-align: justify;">The scrip opened at Rs. 5100.00 and has touched a high and low of Rs. 5300.00 and Rs. 5100.00 respectively. So far 465 shares were traded on the counter.</p><p style="text-align: justify;">The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 7208.00 on 06-Feb-2024 and a 52 week low of Rs. 3102.00 on 20-Apr-2023.</p><p style="text-align: justify;">Last one week high and low of the scrip stood at Rs. 5300.00 and Rs. 4050.15 respectively. The current market cap of the company is Rs. 13142.13 crore.</p><p style="text-align: justify;">The promoters holding in the company stood at 75.00% while Institutions and Non-Institutions held 5.42% and 19.58% respectively.</p><p style="text-align: justify;">AstraZeneca Pharma India has received permission to import for sale and distribution of Trastuzumab deruxtecan lyophilized powder for concentrate for solution for infusion 100mg (Enhertu) from the Central Drugs Standard Control Organisation, Directorate General of Health Services, Government of India. </p><p style="text-align: justify;">Trastuzumab deruxtecan is indicated for the treatment of adult patients with unresectable or metastatic HER2-Low (IHC 1+ or IHC 2+/ISH-) breast cancer who have received a prior chemotherapy in the metastatic setting or developed disease recurrence during or within 6 months of completing adjuvant chemotherapy.</p><p style="text-align: justify;">It is also indicated for the treatment of adult patients with locally advanced or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma who have received a prior trastuzumab based regimen.</p><p style="text-align: justify;">The receipt of this permission paves way for the launch of Trastuzumab deruxtecan lyophilized powder for concentrate for solution for infusion 100mg (Enhertu) in India for the specified additional indications, subject to the receipt of related statutory approvals, if any.</p><p style="text-align: justify;">AstraZeneca Pharma India is a global biopharmaceutical company. The company is engaged in the discovery, development and commercialization of medicines for core areas of healthcare, including cardiovascular/metabolic disease, cancer and respiratory, inflammatory and autoimmune disease. The company operates through two segments Healthcare and Clinical Trial.</p> |
| 11-Mar-2024 | AstraZeneca Pharma India, Mankind Pharma enter into agreement | <p style="text-align: justify;">AstraZeneca Pharma India and Mankind Pharma have entered into an agreement for exclusive distribution of AstraZeneca's budesonide and formoterol fumarate dihydrate (inhaled corticosteroid (ICS) and long-acting beta-agonist (LABA) combination) brand Symbicort in India. AstraZeneca will retain the intellectual property rights to budesonide and formoterol fumarate dihydrate and will continue to be the Marketing Authorisation Holder (MAH) and import license. </p><p style="text-align: justify;">With an expansive distribution network including close to 16,000 field force and more than 13,000 stockists across India, Mankind Pharma has positioned itself as a leader in ensuring availability and access to quality pharmaceuticals across the country, including small towns and rural areas.</p><p style="text-align: justify;">AstraZeneca Pharma India is a global biopharmaceutical company. The company is engaged in the discovery, development and commercialization of medicines for core areas of healthcare, including cardiovascular/metabolic disease, cancer and respiratory, inflammatory and autoimmune disease. The company operates through two segments Healthcare and Clinical Trial.</p> |
| 11-Mar-2024 | Astrazeneca Pharma India informs about press release | <div style="text-align: justify;">Astrazeneca Pharma India has enclosed copy of press release in connection with a Distribution and Promotion Agreement entered into by the Company with Mankind Pharma for the distribution of budesonide and formoterol fumarate dihydrate (brand name Symbicort) in India. Further, details as required under the SEBI Circular SEBI/HO/CFD/CFD-PoD1/P/CIR/2023/123 dated July 13, 2023 attached as Annexure - A, in this regard.</div><div style="text-align: justify;"><br></div><div style="text-align: justify;">The above information is a part of company's filings submitted to BSE. </div> |
| 20-Feb-2024 | AstraZeneca Pharma India informs about change in role of senior management personnel | <p style="text-align: justify;">Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, AstraZeneca Pharma India has informed about the change in role of Amit Bhakri, currently the Business Unit Director - Biopharmaceutical Business Unit. He will be transitioning from the said role with effect from close of business hours on March 31, 2024, as he takes up another responsibility within AstraZeneca group. Further, it has informed that based on the recommendation of the Nomination and Remuneration Committee, the Board of Directors of the Company have approved the appointment of Ayush Kumar Agarwal as Business Unit Director- Biopharmaceutical Business Unit with effect from April 1, 2024. Currently he is the Director – Commercial excellence and will continue leading the same in the interim till a replacement for the said position is filled. In this regard, it has enclosed the details as required under the SEBI Circular SEBI/HO/CFD/CFD-PoD1/P/CIR/2023/123 dated July 13, 2023 attached as Annexure – A.</p><p style="text-align: justify;">The above information is a part of company's filings submitted to BSE.</p> |
| 20-Jan-2024 | AstraZeneca Pharma gets nod to import pharmaceutical formulations of new drug for sale | <p style="text-align: justify;">AstraZeneca Pharma India has received permission to import pharmaceutical formulations of new drug for sale or for distribution in Form CT-20 from Central Drugs Standard Control Organisation for Andexanet alfa powder for solution for infusion 200 mg (Andexxa).</p><p style="text-align: justify;">Through this approval, Andexanet alfa is indicated for patients treated with FXa inhibitors (apixaban or rivaroxaban) when reversal of anticoagulation is needed due to life-threatening or uncontrolled bleeding.</p><p style="text-align: justify;">The receipt of this permission paves way for the launch of Andexanet alfa powder for solution for infusion 200 mg (Andexxa) in India for the specified indication, subject to the receipt of related statutory approvals, if any.</p><p style="text-align: justify;">AstraZeneca Pharma India is a global biopharmaceutical company. The company is engaged in the discovery, development and commercialization of medicines for core areas of healthcare, including cardiovascular/metabolic disease, cancer and respiratory, inflammatory and autoimmune disease. The company operates through two segments Healthcare and Clinical Trial.</p> |
| 20-Jan-2024 | Astrazeneca Pharma India informs about updates | <div style="text-align: justify;">Astrazeneca Pharma India has informed that AstraZeneca Pharma India has received permission to Import pharmaceutical formulations of new drug for sale or for distribution in Form CT-20 from Central Drugs Standard Control Organisation for Andexanet alfa powder for solution for infusion 200mg (Andexxa).</div><div style="text-align: justify;"><br></div><div style="text-align: justify;">The above information is a part of company's filings submitted to BSE.</div><div style="text-align: justify;"><br></div> |
| 21-Dec-2023 | AstraZeneca Pharma to launch Trastuzumab deruxtecan in January 2024 | <p style="text-align: justify;">AstraZeneca Pharma India is planning to launch Trastuzumab deruxtecan 100mg/5mL vial lyophilized powder (Enhertu) in January 2024 in India. Enhertu is indicated for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have received a prior anti-HER2-based regimen.</p><p style="text-align: justify;">AstraZeneca Pharma India is a global biopharmaceutical company. The company is engaged in the discovery, development and commercialization of medicines for core areas of healthcare, including cardiovascular/metabolic disease, cancer and respiratory, inflammatory and autoimmune disease. The company operates through two segments Healthcare and Clinical Trial.</p><div style="text-align: justify;"><br></div> |
| 21-Dec-2023 | AstraZeneca Pharma shines on planning to launch Trastuzumab deruxtecan in January 2024 | <p style="text-align: justify;">Astrazeneca Pharma India is currently trading at Rs. 4688.55, up by 74.85 points or 1.62% from its previous closing of Rs. 4613.70 on the BSE.</p><p style="text-align: justify;">The scrip opened at Rs. 4700.00 and has touched a high and low of Rs. 4884.45 and Rs. 4676.35 respectively. So far 502 shares were traded on the counter.</p><p style="text-align: justify;">The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 5000.55 on 10-Nov-2023 and a 52 week low of Rs. 3102.00 on 20-Apr-2023.</p><p style="text-align: justify;">Last one week high and low of the scrip stood at Rs. 4884.45 and Rs. 4602.25 respectively. The current market cap of the company is Rs. 11534.25 crore.</p><p style="text-align: justify;">The promoters holding in the company stood at 75.00%, while Institutions and Non-Institutions held 5.11% and 19.90% respectively.</p><p style="text-align: justify;">AstraZeneca Pharma India is planning to launch Trastuzumab deruxtecan 100mg/5mL vial lyophilized powder (Enhertu) in January 2024 in India. Enhertu is indicated for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have received a prior anti-HER2-based regimen.</p><p style="text-align: justify;">AstraZeneca Pharma India is a global biopharmaceutical company. The company is engaged in the discovery, development and commercialization of medicines for core areas of healthcare, including cardiovascular/metabolic disease, cancer and respiratory, inflammatory and autoimmune disease. The company operates through two segments Healthcare and Clinical Trial.</p><div style="text-align: justify;"><br></div> |
| 21-Dec-2023 | Mazagon Dock Shipbuilders, Deepak Nitrite and REC to see some action today | <p style="text-align: justify;"><span style="font-weight: bold;">Mazagon Dock Shipbuilders</span> (MDL) has signed a contract with Acquisition wing of Ministry of Defence for Construction and Delivery of six Next generation Offshore Patrol Vessels (NGOPVs) for Indian Coast Guard (ICG) on December 20, 2023.</p><p style="text-align: justify;"><span style="font-weight: bold;">Deepak Nitrite</span>'s wholly owned material subsidiary -- Deepak Phenotics (DPL) has received approval from board of directors for execution of binding Term Sheet between DPL and Petronet LNG (PLL) for offtake of 250 KTPA of Propytene and 11 KTPA of Hydrogen from Petronet Petrochemical Project at Dahej, Gujarat for a period of 15 years from the date of first supply of Propylene and Hydrogen by PLL to DPL.</p><p style="text-align: justify;"><span style="font-weight: bold;">REC</span>'s wholly owned subsidiary -- REC Power Development & Consultancy has incorporated wholly owned subsidiary in the name of Kankani Power Transmission. The said company is also subsidiary company of REC, in terms of the provisions of Section 2(87) of the Companies Act, 2013. The company has been incorporated to develop Transmission system for ‘Rajasthan Intra-state Transmission Package 3 (P3)'.</p><p style="text-align: justify;"><span style="font-weight: bold;">Raymond</span>'s wholly owned subsidiary-- Raymond Lifestyle has incorporated a wholly owned subsidiary company by the name ‘Ten X Realty East' on December 20, 2023 to undertake redevelopment project(s). TXREL has been incorporated with the object to undertake real estate business. </p><p style="text-align: justify;"><span style="font-weight: bold;">Bank of India </span>has infused Rs 19.2 crore in its mutual fund arm Bank of India Investment Managers. Bank of India Investment Managers is 100% subsidiary of Bank of India. However, the bank did not disclose the reason for capital infusion into the mutual fund arm. </p><p style="text-align: justify;"><span style="font-weight: bold;">DCB Bank </span>has entered into a co-lending business alliance with Easy Home Finance (EASY) - India's leading mortgage Tech Company, to offer affordable home loans in the country. This alliance seeks to leverage DCB Bank's expertise in the affordable housing segment and EASY's tech capabilities to enable quick disbursement of affordable home loans and fulfill the dream of many an Indian of owning a home, come true.</p><div style="text-align: justify;"><span style="font-weight: bold;">AstraZeneca Pharma India</span> is all set to launch Enhertu in January 2024 in India. Trastuzumab deruxtecan (Enhertu) is indicated for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have received a prior anti-HER2-based regimen.</div> |
